Retina360: Advances in the Management of Neovascular AMD and Sustained Drug Delivery for Retinal Diseases
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Overview
Provider Statement
This continuing education activity is provided by 
Support Statement
This activity is supported by independent medical education grants from Regeneron Pharmaceuticals, Inc.; Astellas; Alimera Sciences, Inc.; Ocular Therapeutix, Inc.; Outlook Therapeutics; and REGENXBIO Inc.
Activity Description
The continued evolution of treatment protocols and imaging modalities for the management of retinal diseases offers the potential to further optimize visual and anatomical outcomes for patients with these diseases. Furthermore, with the addition of newly approved therapies that have longer durations of action, sustained drug delivery systems, and emerging novel therapies, it can be challenging to stay abreast of the numerous and ongoing therapeutic advances. In this CE activity, experts in the field review innovations in imaging that can improve the diagnosis and monitoring of neovascular age-related macular degeneration (nAMD) and evaluate the latest updates in therapeutic regimens for the optimal long-term management of these patients. In addition, they will evaluate the safety and efficacy of currently available and emerging sustained delivery platforms for the management of patients with nAMD and diabetic macular edema (DME).
Target Audience
The intended audience for this activity is US-based retina specialists and ophthalmologists involved in the management of patients with retinal diseases.
Learning Objectives
Upon successful completion of this educational activity, participants should be better able to:
- Integrate the latest information about advances in imaging and treatment into practice to improve the management of patients with nAMD.
- Summarize innovations in imaging that can improve the diagnosis and management of retinal diseases.
- Describe current evidence about the safety and efficacy of sustained delivery platforms in the management of patients with nAMD and DME.
Activity Chair
Rishi P. Singh, MD
Staff Physician and President
Cleveland Clinic Martin Hospitals
Stuart, FL
Professor of Ophthalmology
Lerner College of Medicine
Case Western Reserve University
Cleveland, OH
Faculty
Margaret A. Chang, MD, MS
Senior Partner
Retinal Consultants of Sacramento
Sacramento, CA
Judy E. Kim, MD, FARVO, FASRS
Jean and Tom Walter Distinguished Chair of Ophthalmology
in Honor of James P. McCulley, MD
Vice Chair of Education
Medical Director of Clinical Research
University of Texas Southwestern Medical Center
Dallas, TX
Yasha Modi, MD
Associate Professor of Ophthalmology
New York University
New York, NY
Director, Retina Service
Wills Eye Hospital
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA
Planner/Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Accreditation
In support of improving patient care, Vindico Medical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
Vindico Medical Education designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, January 31, 2025, to January 30, 2026.
How to Participate in This Activity and Obtain CE Credit
To participate in this activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 5 of the 7 posttest questions correctly. If a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Disclosures
Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Relationship information is accurate at the time of content development.
Activity Chair and Faculty report the following relevant financial relationship(s)
Margaret A. Chang, MD, MS
Consultant: AbbVie/Regenxbio, Astellas, EyePoint, Genentech, Ocular Therapeutix, Oculis, Zeiss
Speaker Contracted by Ineligible Company: Genentech
Independent Research Contractor: Alexion, Boehringer Ingelheim, EyeBio, Mylan, NGM, Novartis, OcuTerra, Outlook
Judy E. Kim, MD, FARVO, FASRS
Advisor: AbbVie, Amgen, Apellis, Bausch + Lomb, Clearside, DORC, EyePoint, Notal Vision, Regeneron
Consultant: Genentech/Roche, Notal Vision, Outlook Therapeutics
Yasha Modi, MD
Consultant: Alcon, Alimera, Allergan, Apellis, Astellas, DORC, EyePoint, Genentech, IVERIC bio, Neurotech, Notal Vision, Opthea, Regeneron, Thea, Zeiss
Carl D. Regillo, MD, FACS
Consultant: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, Aviceda, Bausch + Lomb, BioCryst, Clearside, Cognition Therapeutics, Coherus, EyePoint, Genentech, IVERIC bio, Janssen, jCyte, Kodiak, Kyoto Drug Development, Lineage Cell Therapeutics, Merck, Neurotech, NGM Bio, Novartis, Novelty Nobility, Ocugen, Ocuphire, OcuTerra, Opthea, Outlook, Ray, Regeneron, Regenxbio, Sandoz, Stealth BioTherapeutics, Théa, Zeiss, Zip Bio
Independent Research Contractor: 4DMT, Adverum, Allergan, Annexon, Apellis, Astellas, EyePoint, Genentech, Gyroscope, IVERIC bio, Janssen, Kodiak, Lineage Cell Therapeutics, NGM Bio, Notal Vision, Novartis, Ocugen, OcuTerra, Opthea, Regeneron, Regenxbio
Stock Options: Aviceda, Ocugen
Rishi P. Singh, MD
Consultant: Alcon, Apellis, Bausch + Lomb, EyePoint, Genentech, IVERIC bio, Regenxbio, Regeneron, Zeiss
Independent Research Contractor: Janssen
Planner/Reviewer reports the following relevant financial relationship(s)
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.
Vindico Medical Education staff report the following relevant financial relationship(s)
No relevant financial relationships to disclose.
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage
The audience is advised that this continuing education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2025 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any Vindico Medical Education continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the FDA. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
Procedures for Reporting Copyright Infringement
If you suspect that any content in this activity violates your copyright, you can request the removal of such content or restrict access to it by contacting our designated copyright agent (as outlined below). In your email, kindly provide the following details:
- Specify the copyrighted work you believe has been infringed upon.
- Describe the work and, if possible, include the location (eg, URL) of an authorized version of the work.
- Share your name, address, telephone number, and, if available, your email address.
- Assert that you genuinely believe that the use of the materials in question is not authorized by the copyright owner, its agent, or the law.
- Confirm that the information you have provided is accurate and send an attestation, "under penalty of perjury," that you are either the copyright owner or have the authority to act on behalf of the copyright owner.
- Provide a signature or its electronic equivalent from the copyright holder or a representative authorized to act on their behalf.
Our agent for copyright issues relating to this web activity is as follows:
Vindico Medical Education, LLC
Attn: Faith Bantivoglio
6900 Grove Road, Building 300
Thorofare, NJ 08086
fbantivoglio@vindicocme.com
or call: 856-994-9400, ext. 614
CE Questions?
Contact us at cme@vindicoCME.com